The U.S. Department of Labor (DOL) needs to recognize in regulation that individuals receiving incentives for participation in marketing research are independent contractors, not employees, according to the Insights Association.

August is normally quiet in Washington, DC, but in keeping with the theme of 2020, this month has been more frenetic. While we beat back new taxes on the insights industry, the Insights Association has had to tangle with the demise of the U.S.-EU Privacy Shield for data transfer, further pandemic relief, some new threats to pharma MR, the finalization of CCPA, and an attempt to rush the 2020 Census that threatens the statistical viability of most marketing research and data analytics in the U.S.

The Insights Association has been racking up advocacy wins for our members in the areas of pharmaceutical research, small business loan forgiveness, telephone research, and jury trial research.

In finalizing Maine’s ban on pharmaceutical manufacturer gifts to health care practitioners, the Maine Board of Pharmacy responded to the Insights Association that it should not restrict respondent incentives for participation in bona fide marketing research.

The Insights Association has scored several policy victories in recent months – on Capitol Hill and in states across the U.S. Here are some of the highlights with content links for you and your team, all made possible by your membership.

A look back, counting down the Insights Association's top seven advocacy wins from the last decade that helped our marketing research and data analytics industry members create competitive advantage.

Insights Association lobbyist Howard Fienberg provides a 2019 update on legislation and regulation impacting the marketing research and data analytics industry for Quirks magazine.

The Insights Association helped Arkansas, Oklahoma, and Tennessee approve changes this year harmonizing their treatment of independent contractors, including respondents who receive incentives for their participation in research studies.

Each time the state of Minnesota has tried to clarify treatment of respondent incentives for the participation of health care practitioners in marketing research sponsored by pharmaceutical manufacturers, companies still end up confused. What do the law, regulations and guidance tell us?

Legislation in the city of Philadelphia that would have cut off pharmaceutical marketing research with doctors was defeated in the city council yesterday.